{
  "docId": "019de073-b144-743c-94c4-bc5a80eb44df",
  "docSlug": "9540d42c57dd536e8cb82c97bd211004",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 50 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7794254,
  "pageNumber": 43,
  "pageCount": 50,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide highlights the clinical need for a long-acting progesterone delivery system for preterm birth prevention and IVF support.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-b144-743c-94c4-bc5a80eb44df/43",
  "deckHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df",
  "deckJsonHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df.json",
  "deckAnchorHref": "/decks/019de073-b144-743c-94c4-bc5a80eb44df#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.68,
        "w": 0.31,
        "x": 0.65,
        "y": 0.22
      },
      "kind": "callout",
      "text": "Current products for delivery of progesterone for prevention of preterm birth, as well as luteal phase support in ART, are limited to daily vaginal or intramuscular injectable dosage forms, which have limitations in patient comfort, convenience, and outcomes. The IVR is designed to deliver bio-identical progesterone continuously over a 14-day period and is being developed as a more convenient treatment option.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cdb58b39-da18-45a0-8ad5-0c5efe78c033",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.04,
        "y": 0.62
      },
      "kind": "list",
      "text": "Assisted Reproductive Technologies (ART)/IVF: As women wait longer to have children, infertility risk increases. 12-15% of couples cannot conceive after 1-year of unprotected sex. 20% of US women have their first child after age 35.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a6266e0-cf61-42e6-a775-79677c4769cb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.58,
        "x": 0.04,
        "y": 0.42
      },
      "kind": "list",
      "text": "NIH Grant Funding for PTB Program: Potential for up to $2.3 million in NIH grant funding to support DARE-PTB1 development. Notice of award for initial $300,000 in grant funding announced Aug 2020.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6a9d6f8f-4319-410e-a42e-82d5b3d5c434",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.13,
        "w": 0.58,
        "x": 0.04,
        "y": 0.25
      },
      "kind": "list",
      "text": "Prevention of Preterm Birth (PTB): After steadily declining from 2007 to 2014, the US premature birth rate rose for the fourth straight year in 2018 with ~10% of babies born preterm (<37 weeks).",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1d666cb-7e03-4723-82d7-b0256e9c3b65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "Bio-identical progesterone 14-day IVR for prevention of preterm birth and luteal phase support as part of an IVF treatment plan. There are currently no FDA approved products marketed in the U.S. that do not require daily dosing of progesterone.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c024161-6169-43dd-a53b-397361502346",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.65,
        "x": 0.01,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "*505(b)(2) candidate. 1. Anticipated regulatory pathway... 6. Harris Williams & Co. Fertility market overview. May 2015.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79886f19-5090-409c-8a60-f7113a82c96f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.36,
        "x": 0.32,
        "y": 0.03
      },
      "kind": "title",
      "text": "DARE-FRT1 and DARE-PTB1*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f924e5c0-aa58-40a5-bee7-f1476e383c35",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}